Latest database descriptions

Primary Objective: Progression-free survival in patients aged >= 75 years with metastatic colorectal cancer initiating first line treatment with Avastin®
Secondary Objectives:
- To describe the demographic, clinical and nutritional profiles of the patients and their living conditions and degree of autonomy;
- To describe the change in autonomy criteria;
- To describe the OS;
- To describe Avastin® dosage and regimen;
- To describe the safety profile of Avastin®.

Primary Objective: To estimate the OS of patients treated with cobimetinib in combination with vemurafenib
Secondary Objectives:
- To assess the PFS
- To identify prognostic factors of OS
- To identify prognostic factors of PFS
- To describe response to treatment (overall assessment of the physician)
- To describe time to treatment discontinuation.
- To characterize the targeted AE of cobimetinib in combination with vemurafenib under real-world conditions of useTo describe the long term safety profile of cobimetinib in association with vemurafenib under real-world conditions of use
Exploratory Objectives:
- To describe population of patients treated with cobimetinib in combination with vemurafenib
- To describe the use of cobimetinib in combination with vemurafenib

Determine the incidence of SARS-CoV-2 infection, over an 18-month period after the end of the first lockdown in a group of subjects whose professions involve contact with the general public.
Determine the risk of re-infection after initial infection with SARS-CoV-2 confirmed by a positive serology test.

Describe and document suspected or confirmed cases of SARS-CoV2 nosocomial infections, their clinical spectrum and the determinants (risk factors / protection) at the participating hospitals.